Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report

doi:10.12998/wjcc.v12.i25.5805

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 25

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (164)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

HTML

126

Figures (1-5)

Sum=157

Sep 6, 2024 (publication date) through Jul 15, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Sep 6, 2024; 12(25): 5805-5813
Published online Sep 6, 2024. doi: 10.12998/wjcc.v12.i25.5805

Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report

Ming-Xing Wang, Pei Zhu, Yue Shi, Qing-Ming Sun, Wan-Hui Dong

Ming-Xing Wang, Pei Zhu, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Lu’an 237000, Anhui Province, China

Yue Shi, Qing-Ming Sun, Wan-Hui Dong, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an 237000, Anhui Province, China

Author contributions: Wang MX, Zhu P, Shi Y, Sun QM, and Dong WH designed the research study; Wang MX and Dong WH performed the research; Zhu P, Shi Y, and Sun QM contributed new reagents and analytic tools; Wang MX and Dong WH analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Wan-Hui Dong, MD, Chief Doctor, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, No. 76 Renmin Road, Lu’an 237000, Anhui Province, China. dongwanhui@laszyy.cn

Received: April 19, 2024
Revised: June 22, 2024
Accepted: June 28, 2024
Published online: September 6, 2024
Processing time: 88 Days and 1.9 Hours

Core Tip

Core Tip: In this study, we demonstrate the efficacy of sotorasib in treating advanced non-small cell lung cancer with the KRAS G12C mutation. A patient diagnosed with stage IVB adenocarcinoma, exhibiting pelvic and bone metastases, showed a significant improvement in clinical symptoms post-sotorasib treatment, with no severe side effects observed. This case highlights the potential of targeted therapies in personalized cancer treatment, emphasizing the importance of genomic profiling for therapeutic decision-making.